Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (GlobeNewswire) - Feb 23, 2023 - "During 2023, the Company expects to accomplish the following key business objectives: (i) Complete enrollment in Phase 1/Part A of the ReSPECT-LM trial, expand the number of trial sites, and begin enrollment in Phase 1/Part B; (ii) Present clinical safety and efficacy data of Phase 1/Part A of the ReSPECT-LM trial in the second half of 2023; (iii) Explore potentially synergistic drug combination studies of locally delivered rhenium (186Re) obisbemeda and promising systemic therapies in relevant preclinical models of LM; (iv) Finalize and submit an FDA IND application to treat pediatric patients with ependymoma and high-grade glioma and begin enrollment."
IND • P1 data • Preclinical • Trial status • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor
|